Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Krystal Biotech

Krystal Biotech Clears Technical Benchmark, Hitting 80-Plus RS Rating

Krystal Biotech shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Investors Business Daily

Stocks Generating Improved Relative Strength: Krystal Biotech

Stocks Generating Improved Relative Strength: Krystal Biotech

Krystal Biotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Krystal Biotech Stock Sees RS Rating Jump To 91

Krystal Biotech Stock Sees RS Rating Jump To 91

Krystal Biotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

New gene therapy gel is the 1st approved treatment for rare and painful 'butterfly disease'

The U.S. Food and Drug Administration approved a gene therapy for dystrophic epidermolysis bullosa, also known as butterfly disease.

Krystal Biotech Needs to Feed the Goldfish in 2023

Development delays across the pipeline risks losing interest on Wall Street, which has the attention span of a goldfish.

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Biotech Can't Conquer the Lungs. Will These Stocks Succeed?

Biotech Can't Conquer the Lungs. Will These Stocks Succeed?

The lungs have evolved to keep things out. Can these biotech stocks get drugs in?

Krystal Biotech Files To Seek Approval For Skin Disease Candidate

Krystal Biotech Files To Seek Approval For Skin Disease Candidate

Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of patients with dystrophic epidermolysis bullosa (DEB).

Krystal Biotech Stock Flashes Renewed Technical Strength

Krystal Biotech Stock Flashes Renewed Technical Strength

A Relative Strength Rating upgrade for KrystalBiotech shows improving technical performance.

Investors Business Daily

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade

KrystalBiotech sees its Relative Strength Rating enter the elite 90-plus level.

Investors Business Daily

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities.

1

Organisations

Food and Drug Administration

BofA Securities

B of A Securities

European Medicines Agency

US Food and Drug Administration

Jazz Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Kidney Transplant

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

231,563 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play